Klebsiella pneumoniae Infection in Alveolar Type II Epithelial Cells; Antibiotic-Vitamin Combination Therapeutic Effect
Öz
Aim: In this study, it was aimed to establish an infection model with Klebsiella pneumoniae on A549 Lung cancer cell line and to evaluate the effect of additional vitamins on the antibacterial effect of ampicillin sulbactam in the treatment. Cell culture and pathology results were determined in parallel with microbial analysis.
Methods: Minimal inhibitory concentration (MIC), fractional inhibitory concentration (FIC), biofilm optical density of ampicillin sulbactam, vitamins E, K1 and P on Klebicella pneumoniae ATCC 700603 strain were determined. Cytotoxic activity on A549 cancer cell line in parallel with microbial analysis and pathology results were determined.
Results: Ampicillin Sulbactam MIC dose range used in the treatment of Klebsiella pneumoniae infection is 16 mg/L. Looking at the FIC dose ranges, Vitamin K1+Ampicillin sulbactam, Vitamin P+Ampicillin sulbactam 2.5mg/ml+0.5µg/ml, Vitamin E+Ampicillin sulbactam 5mg/ml+0.5µg/ml, K1+P+E+Ampicillin sulbactam 2,5mg/ml+2.5mg/ml+5mg/ml+0.5µg/ml it was determined that it was. It was determined that it has a synergistic effect in combination with vitamins K1 and P antibiotics. In addition, in the presence of biofilm below 570 nm, the OD values of K1, P, E and K1+P+E+ antibiotic combinations were found to be 1.006, 0.969, 1.096 and 1.015, respectively. As a result of cell culture studies and evaluation of pathology results, it was determined that increasing the dose of Ampicillin sulbactam to 8 µg/ml increased the antibacterial effect and the vitamin combination was more effective.
Conclusions: Antibiotic and vitamin combination was found to be more effective in Klebsiella pneumoniae infection in our study. This situation contributes to the search for alternative antimicrobials.
Anahtar Kelimeler
Lung cancer, Antibacterial activity, Antibiotic resistance, Biofilm, Synergistic effect, Vitamin
Kaynakça
- Ding L, Yang Z, Lu J, Ma L, Liu Y, Wu X, et al. Characterization of phenotypic and genotypic traits of Klebsiella pneumoniae from lung cancer patients with respiratory infection. Infect Drug Resist 2020; 237-245.
- Wyres KL, Lam MM, Holt KE. Population genomics of Klebsiella pneumoniae. Nat Rev Microbiol 2020;18(6): 344-359.
- Wang G, Zhao G, Chao X, Xie L, Wang H. The characteristic of virulence, biofilm, and antibiotic resistance of Klebsiella pneumoniae. Int J Environ Res Public Health 2020; 17 (17): 6278.
- Padmini N, Ajilda AAK, Sivakumar N, Selvakumar G. Extended spectrum β‐lactamase producing Escherichia coli and Klebsiella pneumoniae: critical tools for antibiotic resistance pattern. J Basic Microbiol 2017; 57(6): 460-470.
- Navon-Venezia S, Kondratyeva K, Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev 2017;41:252-275.
- Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012;67:2793-2803.
- Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011;53:60-67.
- Loh AH, Cohen AH. Drug-induced kidney disease-pathology and current concepts. Ann Acad Med Singapore 38(3): 240-250.
- Poirel L, Nordmann P. Lack of polymyxin resistance among carbapenemase-producing Enterobacteriaceae in a university hospital in China. Infect Dis (London, England) 2017; 49(7): 556-557.
- Zhang HM, Wakisaka N, Maeda O, Yamamoto T. Vitamin C inhibits the growth of a bacterial risk factor for gastric carcinoma: Helicobacter pylori. Cancer: Interdisciplinary International Journal of the American Cancer Society 1997; 80(10): 1897-1903.